NCT04939844View on ClinicalTrials.gov

REST - Replacing Steroids in the Transplant Ineligble

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

June 29, 2021

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions
Multiple Myeloma
Interventions
DRUG

Isatuximab, bortezomib, lenalidomide, dexamethason

All participants will receive the same treatment as described under arm.

Trial Locations (4)

4000

Zealand University Hospital, Roskilde

Unknown

Oslo University Hospital, Oslo

Helse Stavanger HF, Stavanger

St. Olav University Hospital, Trondheim

All Listed Sponsors
collaborator

Nordic Myeloma Study Group

OTHER

collaborator

St. Olavs Hospital

OTHER

collaborator

Helse Stavanger HF

OTHER_GOV

lead

Oslo University Hospital

OTHER